Immunai, an Israeli biotech company, announced earlier this week that it has signed an agreement with Bristol Myers Squibb in which the company will apply its AMICA-OS artificial intelligence operating system to BMS clinical programs. The collaboration, announced in New York City, is designed to generate immune-centric insights that support trial design and decision-making, Immunai said.
Immunai is a biotechnology company working to comprehensively map and decode the immune system with single-cell biology and AI to make new therapeutic discoveries, accelerate drug development, and improve patient outcomes.
Under the agreement, Immunai will analyze high-dimensional immune data to help clarify mechanisms of action, identify patient subgroups, discover biomarkers, and guide data-informed choices across development stages, according to the company.
“Understanding the immune system at the level required to guide clinical development remains one of the most complex challenges in drug development,” Immunai CEO Noam Solomon said. He added that AMICA-OS is intended to translate complex immune data into actionable insights that may advance better therapies for patients.
“At Bristol Myers Squibb, we are focused on leveraging innovative approaches that deepen our understanding of patient biology and treatment response,” said Bryan Campbell, Senior Vice President and Head of Drug Development Strategy and Innovation at BMS. He said the work with Immunai would enable advanced AI technologies to generate meaningful immune insights from clinical data.
The companies said the collaboration could expand to additional programs if the initial effort is successful.
Background and context
Immunai’s platform combines single-cell genomics with machine learning to map and decode the immune system for drug development.
The company has expanded industry ties recently. In September 2024, the company announced a multi-year collaboration with AstraZeneca to apply its platform and machine learning to oncology trials, an agreement that began with an $18 million initial phase and an option to expand. In November 2024, Immunai unveiled a separate multi-year partnership with Teva focused on immunology and immuno-oncology research.
The company has also drawn senior pharma leadership. In March 2025, former Pfizer chief scientist Mikael Dolsten joined Immunai’s board to support the integration of AI-driven immunology in drug development. More broadly, Israel’s biotech sector is seeing larger global partnerships, citing Immunai’s expanded $85 million collaboration with AstraZeneca as part of that trend.